SBI Biotech strives for novel drug development targeting cancers and autoimmune diseases. We focus on development of molecule targeting drugs and immune modulation drugs with lower side effects and higher efficacies, based on our technologies on DC platform.
|ILT7 (MEDI7734)||SLE,Sjögren's syndrome,
|Kyowa Hakko Kirin(*2)|
|SBI-3150||Autoimmune diseases caused
by pDCs/activated B cells
|GNKS356 (TLR antagonist)||Psoriasis,
IBD, SLE, etc.
|Cdc7(AS-141/SRA141)||Various cancers||Carna Biosciences, Inc(*4)|
(*1) MedImmune, a group company of AstraZeneca, started Phase I study in 2016 autumn. MedImmune is to provide milestone and loyalty payments to SBI biotech along with the progress of development.
(*2) SBI Biotech licensed out SBI-9674 to Kyowa Hakko Kirin (KHK) in 2016 winter. KHK is to provide milestone and loyalty payments to SBI biotech along with the progress of development.
(*3) SBI Biotech is developing GNKS356 as a therapeutic drug for pustular psoriasis under grant support from AMED* since FY 2015.
* AMED: Japan Agency for Medical Research and Development
(*4) After SBI Biotech has transferred intellectual property of Cdc7 inhibitor to Carna Biosciences, Inc. (CBS) in 2014, CBS entered into the licensing agreement with Sierra Oncology, Inc. SBI Biotech is to receive milestone payments along with the progress of development.